Inhibikase Therapeutics Files 8-K
Ticker: IKT · Form: 8-K · Filed: 2026-04-07T08:09:02-04:00
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: IKAS
TL;DR
IKAS filed an 8-K, check EX-99.1 for updates.
AI Summary
Inhibikase Therapeutics, Inc. filed an 8-K on April 7, 2026, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The filing includes an exhibit (EX-99.1) and an extracted XBRL instance document, indicating potential updates or disclosures related to the company's financial status or business operations.
Why It Matters
This 8-K filing signals that Inhibikase Therapeutics has made a new disclosure to the SEC, which could contain material information relevant to investors.
Risk Assessment
Risk Level: medium — 8-K filings can contain material information, but without specific details in the provided text, the risk level is moderate.
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Filer of the 8-K
- 0001750149 (company) — CIK number for Inhibikase Therapeutics, Inc.
- 2026-04-07 (date) — Filing Date and Period of Report
FAQ
What specific information is disclosed in Exhibit EX-99.1?
The provided text does not specify the content of Exhibit EX-99.1, only that it is part of the 8-K filing.
What is the purpose of the XBRL instance document filed?
The XBRL instance document (d108350d8k_htm.xml) is an extracted document used for financial data reporting in a standardized format.
What does 'Regulation FD Disclosure' mean in this context?
Regulation FD (Fair Disclosure) requires public companies to disclose material non-public information to the public in a broad and non-exclusionary manner.
What are the mailing and business addresses for Inhibikase Therapeutics, Inc.?
The mailing and business addresses are both listed as 1000 N. WEST STREET, SUITE 1200 WILMINGTON DE 19801.
What is the SIC code for Inhibikase Therapeutics, Inc.?
The SIC code is 2836, which corresponds to Biological Products, (No Diagnostic Substances).
Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2026-04-07 08:09:02
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value IKT The Nasdaq Stock Mark
Filing Documents
- d108350d8k.htm (8-K) — 24KB
- d108350dex991.htm (EX-99.1) — 12KB
- g108350g0403235107841.jpg (GRAPHIC) — 4KB
- 0001193125-26-144582.txt ( ) — 158KB
- ikt-20260407.xsd (EX-101.SCH) — 3KB
- ikt-20260407_lab.xml (EX-101.LAB) — 18KB
- ikt-20260407_pre.xml (EX-101.PRE) — 11KB
- d108350d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits. 99.1 Press Release issued by Inhibikase Therapeutics, Inc., dated April 7, 2026, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 7, 2026 INHIBIKASE THERAPEUTICS, INC. By: /s/ Mark Iwicki Mark Iwicki Chief Executive Officer